Pliant Therapeutics Presents Preclinical Data in NASH and PSC at The Liver Meeting 2018
SOUTH SAN FRANCISCO, Calif., Nov. 9, 2018 /PRNewswire/ -- Pliant Therapeutics, Inc., a biotechnology company unraveling and targeting the key biological pathways driving fibrosis, today announced company scientists and research collaborators will present in vivo data highlighting Pliant's clinical product candidates in two posters at The Liver Meeting® 2018 hosted by the American Association for the Study of Liver Diseases (AASLD). Leveraging its discovery engine, Pliant is advancing small-molecule, tissue-specific integrin inhibitors that modulate transforming growth factor beta (TGF-?), a key regulator of physiological healing and pathologic fibrosis.
"Our research continues to support the potential of our approach of integrin inhibition to treat fibrosis in a variety of liver diseases, including nonalcoholic steatohepatitis and primary sclerosing cholangitis," said Scott Turner, Ph.D., vice president of translational sciences at Pliant Therapeutics. "We continue to increase our understanding of the molecular drivers of fibrotic liver diseases and evaluating these drivers in translational models to inform our selection of product candidates to take into the clinic."
Details for the two poster presentations at The Liver Meeting are as follows:
Few investigational compounds for nonalcoholic steatohepatitis (NASH) are directly targeting fibrosis. Pliant has identified an orally available, small-molecule compound for inhibition of ?V?1 mediated TGF-? activation. Given the integrin ?V?1 has been proposed as master regulator of TGF-? activation and hepatic fibrogenesis, Pliant tested the antifibrotic activity of ?V?1 inhibition in CCl4 injured BALB/c mice.
The study results presented by Dr. Turner demonstrated an inhibition of ?V?1-mediated activation of TGF-? significantly reduced CCl4-induced liver fibrosis, warranting further evaluation.
Yury Popov, M.D., Ph.D., assistant professor of medicine, division of gastroenterology, Beth Israel Deaconess Medical Center at Harvard Medical School, and collaborators evaluated three novel, small molecule ?V?6 integrin inhibitors in a mouse model of primary sclerosing cholangitis (PSC):
PLN-1177, a pan RGD integrin inhibitor;
PLN-1561, an ?V?6/?V?1 dual inhibitor;
PLN-1705, an ?V?6 selective inhibitor.
All three compounds significantly reduced serum total bilirubin and inhibited biliary fibrosis as assessed both histologically and biochemically through hepatic collagen levels, with the selective inhibitors having the most potent effects.
Pan RGD integrin inhibitors may present previously unanticipated risks of exacerbated inflammation in the setting of cholestatic liver disease.
The study concluded that partial inhibition of ?V?6 is sufficient to potently reduce fibrosis, and that pan RGD integrin inhibitors may present previously unanticipated risks of exacerbated inflammation in the setting of cholestatic liver disease.
About Pliant Therapeutics Pliant Therapeutics is a biotechnology company unraveling and targeting the key biological pathways driving fibrosis. By leveraging its powerful product discovery engine, Pliant's mission is to develop novel therapeutics that seek to halt progression of fibrotic diseases, ultimately preserving organ function. Founded by a group of seasoned experts in fibrosis biology, medicinal chemistry and translational medicine, Pliant expects to initiate clinical trials with its lead product candidate PLN-74809 in idiopathic pulmonary fibrosis in late 2018, with additional programs to advance into the clinic in 2019. For more information, please visit www.pliantrx.com.
Media Contact: Cambria Fuqua Canale Communications (619) 849-5390 [email protected]
On April 16th, the Yiwu China Commodities City unveiled a new welcoming committee, comprising the region's top women entrepreneurs, to aid international buyers in sourcing local products. Over 120 skilled businesswomen from the committee will provide...
PitchBook, the premier data provider for the private and public equity markets today released The Global VC Ecosystem Dashboard that ranks the world's top startup cities. This dashboard leverages PitchBook data and PitchBook Institutional Research...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
DHGATE Group has won the "Best B2B Cross-Border E-Commerce Marketplace Company China 2024" award at the Global Business & Finance Magazine Awards. The award recognizes leading enterprises with innovation and leadership from various industries, and...